Development of Cationic Quaternary Ammonium Sulfonamide Amino Lipids for Nucleic Acid Delivery
Source abstract
Abstract
Lipid nanoparticles (LNPs) currently comprise the most effective carrier class for the delivery of small RNAs. Among lipid carriers, charge-unbalanced lipids are relatively unexplored synthetically. Herein, we developed and evaluated a novel collection of compounds for small interfering RNA (siRNA) delivery, termed cationic quaternary ammonium sulfonamide amino lipids (CSALs). The formulated CSAL LNPs containing cholesterol, 1,2-distearoyl- sn -glycero-3-phosphocholine, and lipid poly(ethylene glycol) exhibited biophysical property trends directly related to the CSAL chemical structure. Lead CSAL LNPs were identified using an siRNA delivery screen. Further chemical synthesis using a rational structure-guided design showed that the head group structure could alter the p K a and other physical properties that modulated delivery efficacy. Shorter-chained dimethylamino head groups, acetate side chains, and higher tail carbon numbers were favorable for delivery. This led to a further study of A3-OAc-C2Me LNPs, which enabled in vivo delivery to normal mouse lungs and subcutaneous and orthotopic lung tumors. Incorporation of CSALs into liver-targeting formulations shifted the in vivo delivery of these carriers to the lungs. This study highlights the importance of the cationic lipid structure in LNPs and provides further design guidelines for nucleic acid carriers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Simmons Comprehensive Cancer Center, Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States
Funding
Welch Foundation · University of Texas Southwestern Medical Center · Cancer Prevention and Research Institute of Texas · American Cancer Society · Mary Kay Foundation · National Institutes of Health
References (45)
Show source-provided references
1. 10.1038/nrd177510.1038/nrd1775 ↗
2. 10.1038/nrd274210.1038/nrd2742 ↗
3. 10.1038/nmat376510.1038/nmat3765 ↗
4. 10.1038/nbt.261210.1038/nbt.2612 ↗
5. 10.1038/nbt.261410.1038/nbt.2614 ↗
6. 10.1038/nbt.329810.1038/nbt.3298 ↗
7. 10.1016/j.jconrel.2015.02.00310.1016/j.jconrel.2015.02.003 ↗
8. 10.1016/s0168-3659(01)00494-110.1016/s0168-3659(01)00494-1 ↗
9. 10.1021/bc900393r10.1021/bc900393r ↗
10. 10.1021/bc300381s10.1021/bc300381s ↗
11. 10.1016/j.jconrel.2014.04.04710.1016/j.jconrel.2014.04.047 ↗
12. 10.1152/physrev.00002.201210.1152/physrev.00002.2012 ↗
13. 10.1038/nrm233010.1038/nrm2330 ↗
14. 10.1002/anie.20161020910.1002/anie.201610209 ↗
15. 10.1021/jm401375q10.1021/jm401375q ↗
16. 10.1126/science.aal375510.1126/science.aal3755 ↗
17. 10.1021/jm501105n10.1021/jm501105n ↗
18. 10.1016/j.biomaterials.2011.03.04210.1016/j.biomaterials.2011.03.042 ↗
19. 10.1021/bm050357110.1021/bm0503571 ↗
20. 10.1002/anie.20141161510.1002/anie.201411615 ↗
21. 10.1038/nbt140210.1038/nbt1402 ↗
22. 10.1073/pnas.091060310610.1073/pnas.0910603106 ↗
23. 10.1073/pnas.110637910810.1073/pnas.1106379108 ↗
24. 10.1002/anie.20120326310.1002/anie.201203263 ↗
25. 10.1016/j.jconrel.2011.11.01410.1016/j.jconrel.2011.11.014 ↗
26. 10.1073/pnas.132293711110.1073/pnas.1322937111 ↗
27. 10.1038/ncomms527710.1038/ncomms5277 ↗
28. 10.1021/jacs.5b0342910.1021/jacs.5b03429 ↗
29. 10.1073/pnas.152075611310.1073/pnas.1520756113 ↗
30. 10.1021/nn403325f10.1021/nn403325f ↗
31. 10.1038/nbt.160210.1038/nbt.1602 ↗
32. 10.1073/pnas.160688611310.1073/pnas.1606886113 ↗
33. 10.1016/j.biomaterials.2016.12.00110.1016/j.biomaterials.2016.12.001 ↗
34. 10.1002/adma.20140405910.1002/adma.201404059 ↗
35. 10.1038/nbt.258010.1038/nbt.2580 ↗
36. 10.1023/b:pham.0000016251.42392.1e10.1023/b:pham.0000016251.42392.1e ↗
37. 10.1021/bm060300u10.1021/bm060300u ↗
38. 10.1056/nejmoa120876010.1056/nejmoa1208760 ↗
39. 10.1016/j.jconrel.2011.09.09810.1016/j.jconrel.2011.09.098 ↗
40. 10.1038/nnano.2014.8410.1038/nnano.2014.84 ↗
41. 10.1073/pnas.141268611110.1073/pnas.1412686111 ↗
42. 10.1016/j.phrs.2009.11.01310.1016/j.phrs.2009.11.013 ↗
43. 10.1038/gt.2016.4610.1038/gt.2016.46 ↗
44. 10.1021/acs.nanolett.5b0249710.1021/acs.nanolett.5b02497 ↗
45. 10.1038/nbt.347110.1038/nbt.3471 ↗